And platinum medicine next-generation all-human anti-CTLA-4 antibody HBM4003 first patient has been successfully enrolled in the group medication
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, and platinumMedicine sin pharmaceutical(http://announced that its new generation of all-human anti-CTLA-4 antibody HBM4003 has launched the first global clinicaltrial(http://for patients with advanced solid tumors, the first patient has successfully entered the drugabout HBM4003
HBM4003 is the world's first human-derived heavy-chain antibody to enter the clinical research phase, produced from and platinum medicine-specific HCAb all-human antibody technology platformHBM4003 demonstrates its great potential in anti-tumor and safety by enhancing the cytotoxic action (ADCC) of antibody dependence on cell-mediated cells and shortening the half-life of antibodiesCompared to the first generation of anti-CTLA-4 antibodies, HBM4003 showed stronger anti-tumor activity and lower systemdrug(http://exposure in preclinical studies, indicating that it may have significant improvement in clinical efficacyand Platinum Pharmaceuticals presented the preclinical findings of HBM4003 at the American Association for Cancer Research's Annual Meeting (AACR) in April 2019currently in this clinical trial to assess the safety, pharmacokinetic characteristics and initial anti-tumor activity of HBM4003 in patients with advanced solid tumors
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
